Anfield Capital Management’s Regenxbio RGNX Stock Holding History

Anfield Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-640	Closed	-$14.5K	–	90
2022 Q4	$14.5K	Buy	+640	New	+$14.5K	0.01%	84

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Anfield Capital Management's RGNX Position: Q1 2023 in Review

Anfield Capital Management sold out of Regenxbio (RGNX) in Q1 2023, closing a stake of 640 shares — an estimated $14.5K sold.

Anfield Capital Management first reported a position in RGNX in Q4 2022 and held it in 1 quarter. The position peaked at $14.5K in Q4 2022. 174 funds tracked by Wall St. Rank hold RGNX as of Q1 2023.

Anfield Capital Management reported no remaining Regenxbio position as of Q1 2023 after selling out during the quarter.
Anfield Capital Management sold 640 Regenxbio shares in Q1 2023, an estimated $14.5K.
Anfield Capital Management first reported a position in Regenxbio in Q4 2022 and held it in 1 quarter.
Anfield Capital Management's Regenxbio position peaked at $14.5K in Q4 2022.
174 funds tracked by Wall St. Rank held Regenxbio as of Q1 2023.

Based on Anfield Capital Management's 13F filing for Q1 2023, filed 4 May 2023.